Physician profile
Deepa E Nidhiry
NPI 1932305778
$22,524.29
in general payments reported to CMS, 2019-2025
77 companies · $3,982 in 2025
The $3,982 reported for 2025 was more than what 82% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,507 · 2020: $1,914 · 2021: $3,800 · 2022: $2,244 · 2023: $2,848 · 2024: $3,229 · 2025: $3,982.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,728 · Education: $332.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,728.09 |
| Education | $332.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,762.16 | 2019-2025 | Uplizna |
| Abbvie INC. | $2,436.52 | 2021-2025 | |
| Allergan, INC. | $1,563.81 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $1,321.71 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Ucb, INC. | $902.31 | 2019-2025 | Rystiggo, Briviact, Fintepla |
| Pfizer INC. | $830.59 | 2021-2025 | |
| Biogen, INC. | $718.75 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Novartis Pharmaceuticals Corporation | $710.20 | 2019-2025 | |
| Vanda Pharmaceuticals INC. | $631.23 | 2025 | Ponvory |
| Lilly USA, LLC | $551.27 | 2020-2025 | Amyvid, Kisunla, Emgality |
| Sunovion Pharmaceuticals INC. | $503.73 | 2019-2022 | |
| Sk Life Science, INC. | $494.01 | 2020-2025 | |
| Biohaven Pharmaceuticals, INC. | $448.53 | 2020-2021 | |
| Celgene Corporation | $406.05 | 2019-2025 | Zeposia |
| Acadia Pharmaceuticals INC | $369.32 | 2019-2025 | Nuplazid |
Show all 77 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Upsher-Smith Laboratories LLC | $336.88 | 2019-2023 | |
| Harmony Biosciences LLC | $328.71 | 2020-2025 | Wakix |
| Genentech USA, INC. | $297.91 | 2021-2025 | Ocrevus Zunovo, Ocrevus |
| Eisai INC. | $280.71 | 2020-2025 | |
| Alexion Pharmaceuticals, INC. | $277.90 | 2019-2025 | Ultomiris |
| Lundbeck LLC | $277.50 | 2020-2025 | Vyepti, Rexulti |
| Emd Serono, INC. | $276.16 | 2019-2025 | |
| Neurelis, INC. | $270.91 | 2022-2025 | Valtoco |
| Csl Behring | $252.24 | 2019-2024 | Hizentra |
| Catalyst Pharmaceuticals, INC. | $249.33 | 2021-2025 | Fycompa |
| Mdd US Operations, LLC | $249.29 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $206.91 | 2022 | |
| Amneal Pharmaceuticals LLC | $183.14 | 2019-2025 | Ongentys 50mg Capsules 30, Crexont, Rytary |
| Grifols USA, LLC | $175.08 | 2020-2025 | Gamunex-C, Xembify |
| Gt Medical Technologies, INC | $171.96 | 2025 | Gammatile |
| Argenx US, INC. | $168.91 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Neurocrine Biosciences, INC. | $158.13 | 2023-2025 | Ingrezza, Ongentys |
| Aprecia Pharmaceuticals, LLC | $157.25 | 2021-2023 | Spritam |
| Sirtex Medical INC | $140.35 | 2025 | Sir-Spheres Microspheres |
| Tg Therapeutics, INC. | $120.75 | 2023-2025 | |
| Scilex Pharmaceuticals INC. | $119.78 | 2023-2024 | Ztlido |
| Livanova USA, INC. | $117.23 | 2022-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Azurity Pharmaceuticals, INC. | $111.97 | 2023-2025 | Horizant, Horizant |
| Dixi Medical USA Corp | $103.34 | 2023 | |
| Alnylam Pharmaceuticals INC. | $101.76 | 2022-2023 | Onpattro |
| Otsuka America Pharmaceutical, INC. | $99.74 | 2024-2025 | Rexulti |
| Acorda Therapeutics, INC | $90.08 | 2019-2022 | |
| Avion Pharmaceuticals | $88.32 | 2022 | |
| Impel Pharmaceuticals INC. | $84.71 | 2022-2023 | Trudhesa |
| Janssen Biotech, INC. | $83.35 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $82.28 | 2025 | Hyqvia |
| Merz Pharmaceuticals, LLC | $81.11 | 2023-2025 | Inbrija, Xeomin |
| Arbor Pharmaceuticals, INC. | $79.54 | 2021-2022 | |
| Boston Scientific Corporation | $73.12 | 2021-2025 | General - Dbs |
| Endo Pharmaceuticals INC. | $71.62 | 2020 | |
| Axsome Therapeutics, INC. | $69.10 | 2023-2025 | Symbravo, Sunosi |
| Janssen Pharmaceuticals, INC | $68.57 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $64.41 | 2023 | Aptiom |
| Aucta Pharmaceuticals, INC. | $59.71 | 2025 | Motpoly Xr |
| Ani Pharmaceuticals, INC. | $54.13 | 2023 | Purified Cortrophin Gel |
| Coherus Oncology, INC. | $51.39 | 2020-2021 | |
| Tonix Medicines, INC. | $43.36 | 2024 | Zembrace Symtouch |
| Avanir Pharmaceuticals, INC. | $41.87 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $41.49 | 2021-2024 | Wainua |
| Zyla Life Sciences, INC. | $41.32 | 2019-2020 | |
| Kyowa Kirin, INC. | $39.88 | 2020 | |
| Supernus Pharmaceuticals, INC. | $35.75 | 2020-2022 | |
| Merz North America, INC. | $34.91 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $28.39 | 2020-2023 | Opdualag |
| Octapharma USA, INC. | $27.48 | 2022-2023 | Panzyga |
| Neuropace, INC. | $22.77 | 2023 | |
| Averitas Pharma INC. | $21.23 | 2024 | Qutenza |
| Ipsen Biopharmaceuticals, INC | $21.14 | 2025 | Dysport |
| Genzyme Corporation | $20.73 | 2020 | |
| Ge Healthcare | $19.77 | 2019 | |
| Banner Life Sciences, LLC | $18.56 | 2022 | |
| Assertio Therapeutics, INC. | $17.10 | 2020 | |
| Helsinn Therapeutics (U.S.), INC. | $14.64 | 2019 | |
| Promius Pharma LLC | $14.37 | 2019 | |
| Amarin Pharma, INC. | $14.20 | 2021 | |
| Exact Sciences Corporation | $13.32 | 2024 | Cologuard Collection Kit |
| Inogen, INC. | $6.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepa Nidhiry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.